On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to consider seven peptides for the agency's 503A Bulks List — the list that governs which bulk substances compounding pharmacies are legally permitted to use when preparing patient-specific medications. The outcome is worth understanding, both for what it says about where regulatory attention is heading and because it involves several compounds researchers work with regularly.
What the committee recommended
The committee voted to recommend six of the seven peptides for inclusion on the 503A Bulks List:
- BPC-157
- KPV
- TB-500
- MOTS-c
- Semax
- Epitalon
The seventh, Emideltide (also known as DSIP, Delta Sleep-Inducing Peptide), did not receive committee support for inclusion.
What this actually means — and doesn't
It's easy to read a committee vote as a final decision. It isn't. A PCAC recommendation is advisory only — it does not, by itself, add anything to the 503A Bulks List. The FDA (and ultimately HHS) still has to act, and has several paths available: defer entirely, initiate formal rulemaking to revise the list (a process that can take years), or issue enforcement-discretion guidance without a formal rule change. The timeline, and even the eventual outcome, remain genuinely uncertain.
Why this is a different conversation than research use
It's worth being precise about what the 503A Bulks List actually governs: it's specifically about compounding pharmacies preparing individualized medications for human patients under a prescription. That's a distinct regulatory pathway from research peptides sold for laboratory and research use, which is the category every product on this site falls under. This news is relevant background for anyone tracking where the regulatory conversation around these compounds is heading — it isn't a statement about, or change to, the research-use category itself.
Why it's still worth tracking
A committee recommendation, even a non-binding one, tends to shape how a compound is discussed and studied going forward — it reflects where expert and regulatory attention currently sits. For six compounds that already anchor a meaningful share of ongoing peptide research, that's a genuinely useful signal, independent of what the FDA ultimately decides to do with it.
We'll follow this story as the FDA's next steps become clearer.